Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Greenworks
301260
5
Tuoxin Pharmaceutical Group
301089
CN Stock MarketDetailed Quotes
301166 Shanghai Universal Biotech
- 29.59
- +0.27+0.92%
Post Market May 16 15:00 CST
2.56BMarket Cap-1972.67P/E (TTM)
29.75High29.11Low12.86KlotVolume29.27Open29.32Pre Close37.91MTurnover3.12%Turnover Ratio252.91P/E (Static)86.67MShares37.4652wk High1.25P/B1.22BFloat Cap24.3752wk Low35.18Limit Up41.27MShs Float134.13Historical High23.46Limit Down2.18%Amplitude22.34Historical Low0.23Dividend TTM29.48Avg Price6.60KlotAsk0.78%Div YieldTTM100Lot Size5.58KlotBid
Shanghai Universal Biotech Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -20.34%216.37M | -8.82%1.12B | -6.60%827.73M | -3.87%552.51M | -0.91%271.63M | 2.57%1.23B | 2.83%886.22M | 14.35%574.75M | 13.48%274.13M | 7.70%1.2B |
| Operating revenue | -20.34%216.37M | -8.82%1.12B | -6.60%827.73M | -3.87%552.51M | -0.91%271.63M | 2.57%1.23B | 2.83%886.22M | 14.35%574.75M | 13.48%274.13M | 7.70%1.2B |
| Other operating revenue | ---- | --0 | ---- | --0 | ---- | --0 | ---- | --0 | ---- | --0 |
| Total operating cost | -15.38%230.92M | -5.70%1.15B | -3.38%839.96M | 0.58%558.92M | 4.29%272.89M | 12.17%1.21B | 11.84%869.38M | 22.80%555.69M | 22.82%261.67M | 10.63%1.08B |
| Operating cost | -19.23%177.17M | -7.05%915.91M | -4.45%674.26M | -0.28%447.38M | 2.57%219.33M | 6.13%985.36M | 5.49%705.63M | 15.33%448.66M | 14.17%213.84M | 8.94%928.47M |
| Operating tax surcharges | 90.39%705.65K | 58.35%4.91M | 65.85%3.01M | 76.54%1.57M | -24.32%370.64K | 34.64%3.1M | 45.43%1.82M | 14.42%888.31K | 69.63%489.76K | -45.24%2.3M |
| Operating expense | -11.16%28.55M | -12.51%117.19M | -10.55%90.99M | -5.01%61.65M | 9.11%32.14M | 39.42%133.95M | 35.29%101.73M | 40.07%64.9M | 46.11%29.45M | 24.74%96.07M |
| Administration expense | 8.71%10.75M | 29.95%49.21M | 11.70%30.93M | 3.64%19.58M | 10.30%9.89M | 5.67%37.87M | 24.34%27.69M | 28.50%18.89M | 15.84%8.97M | 13.46%35.84M |
| Financial expense | 75.62%-848.29K | -6.05%-4.77M | 19.52%-4.04M | 46.16%-1.93M | 13.78%-3.48M | 68.74%-4.5M | 55.49%-5.02M | 61.11%-3.58M | 41.09%-4.04M | -339.58%-14.4M |
| -Interest expense (Financial expense) | ---- | -49.40%1.04M | ---- | ---- | ---- | 59.20%2.06M | 210.71%703.89K | 564.13%703.89K | --350K | 1,048.34%1.29M |
| -Interest Income (Financial expense) | 27.53%-1.45M | 19.57%-8.21M | 23.90%-5.97M | 36.09%-4.06M | 39.88%-2.01M | 46.30%-10.2M | 48.90%-7.84M | 43.82%-6.35M | 51.82%-3.34M | -438.08%-19M |
| Research and development | -0.32%14.6M | 7.10%62.77M | 19.36%44.81M | 18.26%30.67M | 13.01%14.64M | 70.52%58.61M | 78.65%37.54M | 138.29%25.94M | 193.53%12.96M | 104.98%34.37M |
| Credit Impairment Loss | 40.80%-2.46M | -61.92%-6.15M | -111.06%-5.86M | -181.17%-4.92M | -67.05%-4.16M | 66.26%-3.8M | 72.29%-2.77M | 78.48%-1.75M | -2.19%-2.49M | -275.42%-11.26M |
| Asset Impairment Loss | -224.84%-506.78K | 94.54%-566.34K | 93.33%-94.3K | 665.31%1.09M | 316.54%405.93K | -394.41%-10.37M | -621.82%-1.41M | -639.89%-192.24K | -538.40%-187.46K | -648.82%-2.1M |
| Other net revenue | -52.61%1.28M | 16.20%28.19M | -19.45%19.29M | -16.33%15.62M | -61.14%2.69M | 49.42%24.26M | 133.39%23.94M | 8,910.32%18.67M | 564.98%6.93M | 139.25%16.24M |
| Fair value change income | -33.78%2.54M | -8.71%13.91M | -25.41%10.71M | -29.10%7.24M | -20.65%3.83M | 5.07%15.24M | 5.55%14.35M | 47.09%10.21M | 1,107.52%4.83M | --14.5M |
| Invest income | -26.95%1.54M | 5.06%15.54M | 7.95%10.08M | 4.78%6.98M | 90.10%2.11M | 82.33%14.79M | 1,147.28%9.34M | 1,441.21%6.66M | 2,436.25%1.11M | --8.11M |
| Asset deal income | ---297.67K | -35,325.63%-1.24M | -9,001.78%-902.33K | ---- | ---- | -113.61%-3.51K | ---9.91K | ---9.91K | ---11.89K | 110.88%25.77K |
| Other revenue | -8.14%465.91K | -20.25%6.7M | 20.23%5.36M | 39.53%5.24M | -86.21%507.21K | 20.90%8.41M | -27.22%4.46M | 638.22%3.76M | 696.15%3.68M | -32.52%6.95M |
| Operating profit | -1,029.25%-13.28M | -97.94%735.72K | -82.69%7.06M | -75.60%9.21M | -92.63%1.43M | -72.26%35.71M | -56.95%40.78M | -24.38%37.73M | -28.27%19.39M | -6.63%128.71M |
| Add:Non operating Income | ---- | 7,977.05%117.52K | 134.21%70.87K | 10,456.95%70.2K | -90.20%50 | 36.36%1.46K | 2,926.10%30.26K | -33.50%665 | -49.00%510 | -90.44%1.07K |
| Less:Non operating expense | ---- | -83.65%36.6K | 116.08%464.86K | -92.83%15.42K | ---- | 13.39%223.88K | 419.02%215.14K | 658.59%215.14K | -98.96%295.49 | -3.99%197.43K |
| Total profit | -1,029.22%-13.28M | -97.70%816.64K | -83.58%6.66M | -75.31%9.26M | -92.63%1.43M | -72.39%35.48M | -57.13%40.6M | -24.77%37.52M | -28.19%19.39M | -6.64%128.52M |
| Less:Income tax cost | -87.27%-7.07M | -93.01%-9.33M | -2,463.92%-7.41M | -294.46%-5.83M | -357.97%-3.77M | -122.06%-4.84M | -98.00%313.66K | -66.72%3M | -72.24%1.46M | -24.23%21.92M |
| Net profit | -219.34%-6.21M | -74.83%10.15M | -65.05%14.08M | -56.27%15.1M | -70.97%5.2M | -62.18%40.32M | -49.01%40.28M | -15.52%34.52M | -17.51%17.92M | -1.96%106.6M |
| Net profit from continuing operation | -219.34%-6.21M | -74.83%10.15M | -65.05%14.08M | -56.27%15.1M | -70.97%5.2M | -62.18%40.32M | -49.01%40.28M | --34.52M | -17.51%17.92M | -1.96%106.6M |
| Net profit of parent company owners | -219.34%-6.21M | -74.83%10.15M | -65.05%14.08M | -56.27%15.1M | -70.97%5.2M | -62.18%40.32M | -49.01%40.28M | -15.52%34.52M | -17.51%17.92M | -1.96%106.6M |
| Earning per share | ||||||||||
| Basic earning per share | -216.67%-0.07 | -74.47%0.12 | -65.22%0.16 | -57.50%0.17 | -70.00%0.06 | -61.79%0.47 | -49.45%0.46 | -14.89%0.4 | -20.00%0.2 | -25.90%1.23 |
| Diluted earning per share | -216.67%-0.07 | -74.47%0.12 | -65.22%0.16 | -57.50%0.17 | -70.00%0.06 | -61.79%0.47 | -49.45%0.46 | -14.89%0.4 | -20.00%0.2 | -25.90%1.23 |
| Other composite income | -116.67%-219.14K | 14.67%830.3K | -136.98%-519.65K | -80.33%326.23K | 367.08%1.31M | -73.46%724.06K | -53.94%1.41M | 18.83%1.66M | -3,089.50%-492.26K | 532.41%2.73M |
| Other composite income of parent company owners | -116.67%-219.14K | 14.67%830.3K | -136.98%-519.65K | -80.33%326.23K | 367.08%1.31M | -73.46%724.06K | -53.94%1.41M | 18.83%1.66M | -3,089.50%-492.26K | 532.41%2.73M |
| Total composite income | -198.63%-6.43M | -73.25%10.98M | -67.47%13.56M | -57.38%15.42M | -62.61%6.52M | -62.46%41.04M | -49.19%41.69M | -14.39%36.18M | -19.72%17.43M | 1.14%109.33M |
| Total composite income of parent company owners | -198.63%-6.43M | -73.25%10.98M | -67.47%13.56M | -57.38%15.42M | -62.61%6.52M | -62.46%41.04M | -49.19%41.69M | -14.39%36.18M | -19.72%17.43M | 1.14%109.33M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | Lixin Zhonglian Accounting Firm (Special General Partnership) | -- | -- | -- | Tianji International Accounting Firm (Special General Partnership) | -- | -- | -- | Tianji International Accounting Firm (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting